Skip to main content
RAPS Euro Convergence 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticketed Event
Ticketed Event
Sponsored Presentation
Sponsored Presentation
Learning Level: Foundational
Learning Level: Foundational
New Exhibitor
New Exhibitor
Networking Event
Networking Event
Enterprise Network Member
Enterprise Network Member
Learning Level: Expert
Learning Level: Expert
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Intermediate
Learning Level: Intermediate
Back

Elizabeth Gfoeller, MA

Corporate Director, Regulatory Affairs
MED-EL

Elizabeth Gfoeller is the Corporate Director of Regulatory Affairs of MED-EL, an EU medical device manufacturer headquartered in Innsbruck, Austria. MED-EL is the global innovation leader in hearing loss solutions. To date, MED-EL’s implantable and non-implantable systems marketed in over 134 markets have restored hearing to more than 200,000 individuals worldwide.
Joining MED-EL in 2006, she currently leads the Corporate Regulatory Affairs function responsible for global product licensing, registrations, re-certifications, post-market vigilance activities, regulatory strategies for new product developments and related compliance activities internally within MED-EL and externally to new and changed regulations and standards. She acts as the responsible person for communication with regulatory agencies and engages in lobbying activities.
Previously Elizabeth worked in the mobile telecommunications sector in regulatory compliance and data protection in Vodafone Ireland. Her educational background is in social sciences, with her graduate and post graduate studies in Sociology completed at the University of the Witwatersrand, South Africa where she was active for many years both as a university lecturer and social researcher in the non-government sector researching into diverse issues such as gender violence, adult literacy, trade unions and demilitarisation.

Disclosure information not submitted.

Presentation(s):